AstraZeneca’s Baxdrostat Trial Completion Puts Resistant Hypertension Opportunity in Focus
AstraZeneca ($~AZN) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca (AZN) is running a late-stage study called “A Double-Blind, Randomised, Placebo-Controlled, Multicentre Study Evaluating the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension.” The goal is to see if its drug baxdrostat lowers blood pressure more than placebo in patients whose hypertension stays high despite multiple medicines, a large unmet need that could support a broad market if results are positive.
Baxdrostat is an oral tablet taken once daily in either 1 mg or 2 mg strength, compared with a matching placebo. It is designed to lower blood pressure in adults with uncontrolled or resistant hypertension, potentially offering an add-on option for patients who do not respond well to current therapies.
The trial is an interventional Phase 3 study with patients randomly assigned to different treatment arms. It uses a parallel design, where groups are treated at the same time, and is double-blind with participants, doctors, study staff, and outcome assessors all unaware of who receives baxdrostat or placebo, with the main focus on treatment benefit.
The study was first submitted on 27 March 2024, signaling the formal launch of the program to regulators and investors. The most recent update was filed on 20 April 2026, and the status is now listed as completed on the registry, which means data collection is done and the next step is analysis and potential disclosure of headline results.
For investors, completion of this Phase 3 trial is a key milestone for AZN, as a successful outcome could open a sizable opportunity in difficult-to-treat hypertension and support long-term revenue growth. Until topline data are released, sentiment will hinge on expectations and comparisons with competing blood pressure drugs, and any hint of strong efficacy and clean safety could lift AZN’s valuation and pressure peers in the cardiovascular space.
The study is now completed and recently updated, and further details are available on the ClinicalTrials.gov portal under identifier NCT06344104.
To learn more about ~AZN’s potential, visit the AstraZeneca drug pipeline page.
Disclaimer & DisclosureReport an Issue
